Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
Depending on the study population, the prevalence of clinically significant ILD among RA patients has been reported to range between 5% to 30% or higher.1-3
In addition to being a relatively common complication of RA, ILD confers a higher risk of mortality.2-4
Information from the Label
Interstitial lung disease is not listed among the adverse events listed in the summary of product characteristics.5
Description of the All BARI RA Dataset
The All BARI RA analysis set included 3770 patients with RA who received BARI at a variety of doses from 1 phase 1, 3 phase 2, and 5 phase 3 studies (RA-BEGIN, RA-BEAM, RA-BUILD, RA-BEACON, RA-BALANCE). Data includes a long-term extension study (RA-BEYOND) with
Incidence of Interstitial Lung Disease in the All BARI RA Dataset
In the All BARI RA dataset, the MedDRA preferred term, ILD, was reported as a TEAE in 15 patients treated with BARI (0.4%; 0.1 EAIR); an EAIR of 0.1 per 100 PYE for patients treated with baricitinib is consistent with the background rate of ILD in patients with RA.8
Interstitial Lung Disease Events Leading to Temporary Interruption, Permanent Discontinuation, or Considered Serious
Table 1. Incidence of Interstitial Lung Disease in the All BARI RA Safety Dataset8
All BARI RA (N=3770)
Abbreviations: BARI = baricitinib; EAIR = exposure-adjusted incidence rate; N = number of patients in the safety analysis dataset; n = number of patients in the specified category; RA = rheumatoid arthritis; SAE = serious adverse event; TEAE = treatment emergent adverse event.
Past Medical History
Only 1 patient of the 9 who had events that led to temporary interruption, permanent discontinuation, or were classified as SAEs had a past medical history of ILD. This patient experienced an event >100 days after starting BARI.8
Seven patients of the 9 who had events that led to temporary interruption, permanent discontinuation, or were classified as SAEs were taking methotrexate concomitantly. Additionally, 2 of the patients reported smoking cigarettes.8
Resolution of Event
Seven patients of the 11 who had events that led to temporary interruption, permanent discontinuation, or were classified as SAEs were hospitalized due to ILD, which was resolved after hospitalization. Five patients were treated with antibiotics for pneumonia based on imaging or presentation with fever. Three patients had worsening cases, which resolved after antibiotics or hospitalization.
One SAE was medically significant, the event of moderate severity ILD was ongoing at the time of discontinuation from the study.8
1. Brito Y, Glassberg MK, Ascherman DP. Rheumatoid Arthritis-Associated Interstitial Lung Disease: Current Concepts. Curr Rheumatol Rep. 2017;19(12):79. https://dx.doi.org/10.1007/s11926-017-0701-5
2. Hyldgaard C, Hilberg O, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis. 2017;76(10):1700-1706. https://dx.doi.org/10.1136/annrheumdis-2017-211138
3. Bongartz T, Nannini C, et al. Incidence and mortality of interstitial lungdisease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62(6):1583-1591. https://dx.doi.org/10.1002/art.27405
4. Zamora-Legoff JA, Krause ML, et al. Patterns of interstitial lung disease and mortality in rheumatoid arthritis. Rheumatology (Oxford). 2017;56(3):344-350. https://dx.doi.org/10.1093/rheumatology/kew391
6. Genovese MC, Smolen JS, Takeuchi T, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 7 years: an updated integrated safety analysis. Ann Rheum Dis. 2019;78(2):308-309. http://dx.doi.org/10.1136/annrheumdis-2019-eular.691
7. Genovese MC, Smolen JS, Takeuchi T, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 7 years: an updated integrated safety analysis. Presented as an oral presentation at: European League Against Rheumatism (EULAR) Annual Meeting; June 12-15, 2019; Madrid, Spain.
BARI = baricitinib
EAIR = exposure-adjusted incidence rate
ILD = interstitial lung disease
MedDRA = Medical Dictionary for Regulatory Activities
PYE = patient-years of exposure
RA = rheumatoid arthritis
SAE = serious adverse event
TEAE = treatment-emergent adverse event
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Datum fӧr senaste ӧversyn 2019 M08 09